Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell) filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, confirming that no changes occurred in either its authorised or issued share capital during the month.

At month-end, Mabwell’s total authorised share capital stood unchanged at 446.73 million shares with a par value of RMB 1 each, comprising: • H-shares: 47.13 million shares listed in Hong Kong. • A-shares: 399.60 million shares listed on the Shanghai Stock Exchange.

Issued share capital also remained flat: • H-shares in issue: 47.13 million; no treasury shares held. • A-shares in issue: 398.41 million; treasury shares unchanged at 1.19 million, stemming from a repurchase on 23 December 2025, prior to the Hong Kong listing.

Mabwell confirmed that the public-float requirement for its Hong Kong-listed H-shares—set at 5% of the class’s issued shares—was fully met as of 31 May 2026.

No share options, warrants, convertibles, or other equity‐linked instruments were issued, exercised, or outstanding during the month.

The filing, submitted on 5 June 2026 by Joint Company Secretary Ms. Wang Hefei, affirms compliance with all relevant Hong Kong Stock Exchange listing rules and regulatory obligations.